Charlotte’s Web Holdings says that labeling lawsuits against CBD makers must wait while federal regulators consider how to regulate the hemp extract.
Charlotte’s Web said that the FDA has “exclusive regulatory and enforcement authority as to the labeling and marketing of CBD product,” making it improper for a court to decide whether CBD makers can describe their products as dietary supplements.
Law 360 first reported the filing.
At least four federal judges have paused or rejected CBD labeling lawsuits because of pending FDA action. The federal agency said this week that it continues to review the safety of over-the-counter CBD but has not said when to expect regulations.
Charlotte’s Web trades on the Toronto Stock Exchange as CWEB.